Gillian McGovern, Associate Editor

Survival rates were similar between non-Hispanic African American and non-Hispanic White patients who received treatment, indicating a need to address barriers to multiple myeloma treatment and racial disparities.

Daratumumab and hyaluronidase-fihj in combination with other therapies was previously approved by the FDA in May 2020 for 8 indications in multiple myeloma.

The findings suggest that further research on additional intervention methods and expanding access to hydroxyurea in Africa could benefit young patients with sickle cell disease.

The study used optogenetics to repeatedly activate and inhibit cells, revealing rapid changes in a protein called pyruvate dehydrogenase when cells were inhibited.

Two directors of outpatient services at Allegheny Health Network highlight the significance of Meds-to-Beds in promoting medication adherence while improving patient experience.

Compared to TACE alone, durvalumab plus TACE and bevacizumab reduced the risk of disease progression or death by 23%; however, further research is needed to assess OS.

According to the FDA review, patients with CKD receiving denosumab for osteoporosis who are on dialysis or have CKD-MBD are at the highest risk of severe hypocalcemia.

Compared with chemotherapy, nivolumab plus ipilimumab reduced the risk of disease progression or death by 79%, but further research is needed to assess overall survival.

The results from the preclinical trial can provide a new method of measuring dietary sources of nutrients in the tissue, but further research is needed to confirm the findings in the human brain.

Compared to placebo, a daily multivitamin showed consistent benefits in global cognition and episodic memory across a clinical trial and meta-analysis of 3 trials.

The treatment is for patients with KRAS G12C-mutant metastatic NSCLC who have previously received at least 1 systemic therapy and were not treated with a KRAS G12C inhibitor.

Despite the insignificant differences in efficacy, biomarkers, therapeutic drug level, and ADAs, patients reported a significant number of nocebo effects.

Previously, IgG-hyaluronidase recombinant was approved by the FDA in 2014 for the treatment of primary immunodeficiency in adult patients and has expanded to include some pediatric patients.

Not only were individuals with BMIs of 30 and higher likely to have MGUS, but those who reported heavy smoking and short sleep were also more likely to have detectable levels of MGUS.

According to the authors, the findings may have broad implications for understanding recombination and viral evolution within various organisms.

In addition, patients who were treated with liso-cel therapy had a higher average life expectancy and QALYs, compared to those who were treated with standard care.

Compared to standard of care TKIs, asciminib also presented favorable safety and tolerability profiles with fewer reported AEs among patients.

This combination regimen, which was compared to once-daily insulin glargine U100 with insulin aspart, had also demonstrated a safe and well-tolerated profile with mild AEs.

The accepted sBLA comes after phase 3 clinical trial results which demonstrated better overall survival, progression-free survival, and confirmed overall response rate than chemotherapy in patients with cervical cancer.

The study results also demonstrated isatuximab had safety and tolerability profiles that were consistent with other clinical trials.

Eliminating certain factors within the GRN resulted in the network shutting down, potentially leading to cancer cell death due to an inability to replicate, according to the study authors.

The efficacy of biologics suggests a potential for biologic-based treatment for patients with asthma-chronic obstructive pulmonary disease overlap.

The study results also determined that those who were previously vaccinated against smallpox had a 2.7 times higher immune response than those who were not previously vaccinated.

The investigators advise that the use of bendamustine should be avoided when possible in patients with refractory LBCL who are potential candidates for CAR T-cell therapy.

The new understanding of immune cells could not only contribute to the development of lung disease treatments, but treatments for other organ systems as well.

According to the findings, the use of venetoclax, as well as other new therapies, improved overall survival from 28.6% to 45.3% in non-Hispanic Black patients with AML.

Because alcohol is a driver of HIV-associated comorbidities, the reduction interventions may improve the health of people with HIV.

The drug is the first medicine to be approved for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis that can be self-administered.

The investigators note that psilocybin’s effectiveness in treating depressive symptoms and the positive reception among patients with cancer are encouraging continued research.

The results confirm tebentafusp as a standard of care.